<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503347</url>
  </required_header>
  <id_info>
    <org_study_id>PPHM 0603</org_study_id>
    <nct_id>NCT00503347</nct_id>
  </id_info>
  <brief_title>Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus</brief_title>
  <official_title>A Phase Ib Open-Label, Escalating Repeat-Dose Trial of Bavituximab (Chimeric Anti-Phosphatidylserine Monoclonal Antibody) in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This trial is designed to assess the safety, tolerability, pharmacokinetics and viral&#xD;
      kinetics after multiple infusions of bavituximab in patients co-infected with HCV and HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the safety and tolerability of bavituximab administered as multiple&#xD;
           intravenous (IV) infusions to patients co-infected with HCV and HIV&#xD;
&#xD;
        -  To characterize the pharmacokinetic profile and viral kinetics after multiple&#xD;
           intravenous infusions of bavituximab to patients infected with HCV and HIV&#xD;
&#xD;
        -  To define the maximum tolerated dose (MTD) and/or maximum effective dose (MED) of&#xD;
           bavituximab administered as multiple infusions to patients infected with chronic HCV&#xD;
           infection and HIV&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Adverse events • Laboratory evaluations • Human anti-chimeric antibody • Pharmacokinetic analysis</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of HCV RNA and HIV RNA (PCR)</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatitis C Virus</condition>
  <condition>Hiv Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bavituximab</intervention_name>
    <description>The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent has been obtained&#xD;
&#xD;
          -  Adults 18 years of age or older&#xD;
&#xD;
          -  HIV infection documented by detectable HIV RNA PCR&#xD;
&#xD;
          -  Absolute CD4+ &gt; 300 cells/mm3&#xD;
&#xD;
          -  Chronic hepatitis C infection based on history and detectable serum HCV RNA&#xD;
&#xD;
          -  Serum alanine aminotransferase (ALT) above normal limits and/or historical biopsy&#xD;
             consistent with hepatitis C&#xD;
&#xD;
          -  Complete blood counts within normal limits&#xD;
&#xD;
          -  Normal renal function (serum creatinine within normal limits)&#xD;
&#xD;
          -  PT/INR and aPTT within normal limits&#xD;
&#xD;
          -  All patients of reproductive potential must agree to use an approved form of barrier&#xD;
             contraception or agree not to become pregnant while taking study medications and for&#xD;
             30 days after study completion. Female patients must have a negative serum pregnancy&#xD;
             test at prestudy (not applicable to patients with bilateral oophorectomy and/or&#xD;
             hysterectomy or to those patients who are postmenopausal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HCV or HIV antiviral therapy within 4 weeks of Day 0&#xD;
&#xD;
          -  Prior exposure to any chimeric antibody&#xD;
&#xD;
          -  Any other cause of liver disease other than chronic hepatitis C, such as autoimmune or&#xD;
             alcoholic liver disease.&#xD;
&#xD;
          -  Decompensated clinical liver disease, including a history of prolonged clotting times,&#xD;
             hypoalbuminemia, encephalopathy, treatment for elevated ammonia levels, or ascites&#xD;
&#xD;
          -  Any evidence of clinically significant bleeding defined as gross hematuria,&#xD;
             hemoptysis, or gastrointestinal bleeding&#xD;
&#xD;
          -  Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease or&#xD;
             Hemophilia)&#xD;
&#xD;
          -  Any history of thromboembolic events [e.g., deep vein thrombosis (DVT) or pulmonary&#xD;
             thromboembolism (PE)]. A history of including central venous catheter-related&#xD;
             thrombosis is acceptable if there is documentation of resolution at least 12 months&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Concurrent therapy with oral or parenteral anticoagulants&#xD;
&#xD;
          -  Concurrent hormone therapy (i.e., estrogen contraceptives, hormone replacement,&#xD;
             anti-estrogen)&#xD;
&#xD;
          -  Investigational therapy within 4 weeks of Day 0&#xD;
&#xD;
          -  Major surgery within 4 weeks of Day 0&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)&#xD;
&#xD;
          -  Any history of angina pectoris, coronary artery disease or cerebrovascular accident,&#xD;
             or transient ischemic attack&#xD;
&#xD;
          -  A history of any condition requiring anti-platelet therapy with the exception of&#xD;
             general cardiovascular prophylaxis with aspirin&#xD;
&#xD;
          -  A history of any condition requiring treatment (past or current) with coumarin-type&#xD;
             agents&#xD;
&#xD;
          -  Cardiac arrhythmia requiring medical therapy&#xD;
&#xD;
          -  Serious non-healing wound (including wound healing by secondary intention, ulcer, or&#xD;
             bone fracture)&#xD;
&#xD;
          -  Requirement for chronic daily treatment with NSAIDs, antiplatelet drugs (e.g.,&#xD;
             phosphodiesterase inhibitors, adenosine diphosphate receptor antagonists), or steroids&#xD;
&#xD;
          -  Cancer, autoimmune disease or any disease or concurrent therapy known to cause&#xD;
             significant alteration in immunologic function. Corticosteroids administered as&#xD;
             pre-treatment, or to treat an adverse event, are allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihad Slim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Michael's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark S. Sulkowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University, Center for Viral Hepatitis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Rodriguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orange Coast Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholaos C. Bellos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Infectious Disease Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lydie Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Impact Clinical Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melaine Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Research Consortium of Atlanta (ARCA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Impact Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Coast Medical Center</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University, Center for Viral Hepatitis</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Infectious Disease Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2007</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jill Capps / Clinical Program Manager</name_title>
    <organization>Peregrine Pharmaceuticals</organization>
  </responsible_party>
  <keyword>coinfection with chronic hepatitis C virus and HIV</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bavituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

